| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a722744e77c81c5f5cf415087e2ee92b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_231e23c27735f11d5a6b434a43887dfe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a5e95156255d5fe8b2923c544786e176 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2799-026 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-1205
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12P21-00 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-91 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-566 |
| filingDate |
1999-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8fc605d4bdbd5cc058cbdecb49772191
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c304fc54366abf9c244c14825bb528ff
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f21937f93f670f7da53bb16146445ec3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cd044014d49075e8b269722dd632b702 |
| publicationDate |
2000-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-0017329-A1 |
| titleOfInvention |
Rec2 kinase |
| abstract |
The invention includes a method of phosphorylating a serine containing substrate by incubating the substrate with ATP and an enzyme that is hsRec2 or muRec2 or a derivative thereof. The natural substrates of the kinase activity of Rec2 are the cell cycle control proteins such as p53 and cyclin E. The over expression of Rec2 is known to cause cell-cycle arrest and apoptosis and the invention discloses that these effects are kinase mediated. Accordingly, the invention provides a method of assessing antagonists and agonists of Rec2, which antagonists and agonists would have pharmacological activity. The invention further discloses that there is specific binding between hsRec2 and at least three cell cycle control proteins: p53, PCNA and cdc2. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11160224-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6870075-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10035991-B2 |
| priorityDate |
1998-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |